5.5(top 5%)
impact factor
3.4K(top 5%)
papers
103.0K(top 5%)
citations
115(top 5%)
h-index
5.8(top 5%)
impact factor
3.6K
all documents
113.4K
doc citations
160(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Consensus guidelines for the detection of immunogenic cell deathOncoImmunology2014686
2Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLCOncoImmunology2016545
3Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell deathOncoImmunology2014439
4Role of IL-2 in cancer immunotherapyOncoImmunology2016347
5IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophanOncoImmunology2012338
6IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumorsin vivoOncoImmunology2015336
7Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapyOncoImmunology2014318
8Targeting PD-1/PD-L1 interactions for cancer immunotherapyOncoImmunology2012315
9CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+T cellsOncoImmunology2013311
10EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancerOncoImmunology2017305
11Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancerOncoImmunology2017252
12TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancerOncoImmunology2013251
13Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-β and miR23a transferOncoImmunology2016247
14First oncolytic virus approved for melanoma immunotherapyOncoImmunology2016247
15The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysisOncoImmunology2017247
16Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytesOncoImmunology2018247
17Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligandsOncoImmunology2012246
18PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?OncoImmunology2018243
19Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastasesOncoImmunology2016239
20Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expressionOncoImmunology2015238
21Trial Watch: Immunogenic cell death inducers for anticancer chemotherapyOncoImmunology2015237
22Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancerOncoImmunology2017235
23Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironmentOncoImmunology2015227
24Trial watch: IDO inhibitors in cancer therapyOncoImmunology2014223
25Targeting CD73 in the tumor microenvironment with MEDI9447OncoImmunology2016221
26Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacyOncoImmunology2015219
27CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trialOncoImmunology2018219
28TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBMOncoImmunology2018217
29A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytesOncoImmunology2013216
30Trial watch: Immunogenic cell death induction by anticancer chemotherapeuticsOncoImmunology2017209
31Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cellsOncoImmunology2017209
32The IRF family of transcription factorsOncoImmunology2012205
33CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancerOncoImmunology2017205
34Interaction of tumor-associated macrophages and cancer chemotherapyOncoImmunology2019205
35Are natural killer cells superior CAR drivers?OncoImmunology2014204
36Trial watchOncoImmunology2012203
37Tumor mutational burden is a determinant of immune-mediated survival in breast cancerOncoImmunology2018200
38Insufficient autophagy promotes bronchial epithelial cell senescence in chronic obstructive pulmonary diseaseOncoImmunology2012199
39Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cellsOncoImmunology2015195
40Trial watch: FDA-approved Toll-like receptor agonists for cancer therapyOncoImmunology2012194
41The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200OncoImmunology2017193
42A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumabOncoImmunology2015191
43Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokinesOncoImmunology2017190
44Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinomaOncoImmunology2015189
45Priming of neutrophils toward NETosis promotes tumor growthOncoImmunology2016188
46Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysisOncoImmunology2019187
47Trial WatchOncoImmunology2012184
48Eosinophils: The unsung heroes in cancer?OncoImmunology2018184
49Neutrophil extracellular trapsOncoImmunology2013181
50The exosomes in tumor immunityOncoImmunology2015181